Unveiling MAGEA3: a novel predictive biomarker for bevacizumab resistance in colorectal cancer

Abstract

Aim: Bevacizumab has long been a cornerstone in the treatment of colorectal cancer (CRC), serving as a fundamental antiangiogenic therapeutic option. However, a significant proportion of patients exhibit insensitivity to bevacizumab, and no reliable biomarker has been established to predict treatment efficacy. Notably, while many angiogenic factors in tumors have been extensively studied, they have failed to consistently demonstrate reliable predictive value for patient survival outcomes in CRC. This study is designed to screen tumor biomarkers with predictive value for bevacizumab resistance in CRC.

Methods: Online CRC databases with bevacizumab treatment were downloaded from the GEO datasets along with the TCGA database, which were then analyzed to generate genes overexpressed in bevacizumab non-responders. In vitro experiments using colorectal cancer cell lines were then performed to explore the underlying mechanism of the candidate gene that impacts bevacizumab efficacy. Finally, clinical samples of CRC were collected to validate the predictive effect of the candidate gene on bevacizumab efficacy.

Results: We conducted comprehensive analyses of CRC patient datasets, identifying MAGEA3 as a pivotal gene that is not only highly upregulated in bevacizumab-resistant primary CRC but also strongly associated with poor overall survival prognosis. Our in vitro experiments revealed a novel mechanistic insight: MAGEA3 specifically inhibits the expression and secretion of VEGF through the mTOR signaling pathway in colorectal cancer cells, while exhibiting minimal impact on other key angiogenic factors such as PDGF, FGF, and ANGPT2. This selective regulation of VEGF provides a molecular basis for MAGEA3's role in bevacizumab resistance. Furthermore, we discovered that MAGEA3 significantly impairs mitochondrial function in cancer cells, suggesting an additional layer of complexity in its oncogenic role. Clinically, our findings demonstrated that high baseline levels of MAGEA3 in CRC patients were strongly associated with worse progression-free survival (PFS) following bevacizumab treatment.

Conclusion: Collectively, these findings position MAGEA3 as a promising predictive biomarker for bevacizumab resistance in CRC, offering a potential solution to the longstanding challenge of treatment stratification.

Keywords

Colorectal cancer / bevacizumab resistance / MAGEA3

References

[1] Siegel RL,Fuchs HE.Cancer statistics, 2022.CA Cancer J Clin2022;72:7-33

[2] Cao Y,Ferrara N.Targeting angiogenesis in oncology, ophthalmology and beyond.Nat Rev Drug Discov2023;22:476-95

[3] Hanahan D.The hallmarks of cancer.Cell2000;100:57-70

[4] Ellis LM.Pathways mediating resistance to vascular endothelial growth factor-targeted therapy.Clin Cancer Res2008;14:6371-5

[5] Ince WL,Holden SN.Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.J Natl Cancer Inst2005;97:981-9

[6] Cervantes A,Roselló S.ESMO Guidelines CommitteeElectronic address: [e-mail]. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.Ann Oncol2023;34:10-32

[7] Chen G.Interpretation of the updates of NCCN 2017 version 1.0 guideline for colorectal cancer.Chin J Gastrointest Surg2017;20:28-33. (in Chinese)

[8] Haibe Y,El Hajj H.Resistance mechanisms to anti-angiogenic therapies in cancer.Front Oncol2020;10:221 PMCID:PMC7056882

[9] Yang Z,Bai X,Liu W.Anti-angiogenesis in colorectal cancer therapy.Cancer Sci2024;115:734-51 PMCID:PMC10921012

[10] Zheng Y,Cai J.Matrix stiffness triggers lipid metabolic cross-talk between tumor and stromal cells to mediate bevacizumab resistance in colorectal cancer liver metastases.Cancer Res2023;83:3577-92 PMCID:PMC10618741

[11] Lambrechts D,de Haas S,Scherer SJ.Markers of response for the antiangiogenic agent bevacizumab.J Clin Oncol2013;31:1219-30

[12] Jubb AM,Bai W.Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.J Clin Oncol2006;24:217-27

[13] Simpson AJ,Jungbluth A,Old LJ.Cancer/testis antigens, gametogenesis and cancer.Nat Rev Cancer2005;5:615-25

[14] Doyle JM,Wang J,Potts PR.MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases.Mol Cell2010;39:963-74 PMCID:PMC4509788

[15] Kim KH,Kim IJ,Park JG.Promoter hypomethylation and reactivation of MAGE-A1 and MAGE-A3 genes in colorectal cancer cell lines and cancer tissues.World J Gastroenterol2006;12:5651-7 PMCID:PMC4088165

[16] Wu F,Dong L.miR-1273g silences MAGEA3/6 to inhibit human colorectal cancer cell growth via activation of AMPK signaling.Cancer Lett2018;435:1-9

[17] Xie C,Datta A.Melanoma associated antigen (MAGE)-A3 promotes cell proliferation and chemotherapeutic drug resistance in gastric cancer.Cell Oncol (Dordr)2016;39:175-86

[18] Gao X,Chen G,Ma Y.MAGEA3 promotes proliferation and suppresses apoptosis in cervical cancer cells by inhibiting the KAP1/p53 signaling pathway.Am J Transl Res2020;12:3596-612 PMCID:PMC7407682

[19] Das B.Functional and mechanistic studies reveal MAGEA3 as a pro-survival factor in pancreatic cancer cells.J Exp Clin Cancer Res2019;38:294 PMCID:PMC6615156

[20] Liu XL,Sun DP.Adenovirus-mediated delivery of CALR and MAGE-A3 inhibits invasion and angiogenesis of glioblastoma cell line U87.J Exp Clin Cancer Res2012;31:8 PMCID:PMC3337230

[21] Uphoff CC,Drexler HG.Mycoplasma contamination in human leukemia cell lines. I. Comparison of various detection methods.J Immunol Methods1992;149:43-53

[22] Jiahui W,Youhuan Z.The mitochondrial DNAJC co-chaperone TCAIM reduces α-ketoglutarate dehydrogenase protein levels to regulate metabolism.Mol Cell2025;85:638-651.e9

[23] Schepelmann M,Gushchina V.AOM/DSS induced colitis-associated colorectal cancer in 14-month-old female Balb/C and C57/Bl6 mice-a pilot study.Int J Mol Sci2022;23:5278 PMCID:PMC9104960

[24] Li W,Wu Z.mRNA-lipid nanoparticle-mediated restoration of PTPN14 exhibits antitumor effects by overcoming anoikis resistance in triple-negative breast cancer.Adv Sci (Weinh)2024;11:e2309988 PMCID:PMC11348215

[25] Li W,Zhou C.Chromosomal instability is associated with prognosis and efficacy of bevacizumab after resection of colorectal cancer liver metastasis.Ann Med2024;56:2396559 PMCID:PMC11385633

[26] Verstraete M,Dekervel J.Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial.Br J Cancer2015;112:1314-25 PMCID:PMC4402460

[27] Goede V,Neuneier J.Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy.Br J Cancer2010;103:1407-14 PMCID:PMC2990609

[28] Stremitzer S,Yang D.Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases.Cancer2015;121:1898-905 PMCID:PMC4441595

[29] Pineda CT,Fon Tacer K.Degradation of AMPK by a cancer-specific ubiquitin ligase.Cell2015;160:715-28 PMCID:PMC5629913

[30] Chen A,Doudican N.MAGE-A3 is a prognostic biomarker for poor clinical outcome in cutaneous squamous cell carcinoma with perineural invasion via modulation of cell proliferation.PLoS One2020;15:e0241551 PMCID:PMC7682861

[31] Nobeyama Y.MAGEA3 methylation status is associated with prognosis of malignant peripheral nerve sheath tumor and with neurofibroma type in neurofibromatosis type 1.J Dermatol Sci2016;84:101-4

[32] Garcia J,Sandler AB.Bevacizumab (Avastin^®) in cancer treatment: a review of 15 years of clinical experience and future outlook.Cancer Treat Rev2020;86:102017

[33] Ghalehbandi S,Pranjol MZI.The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF.Eur J Pharmacol2023;949:175586

[34] Kruit WH,Dreno B.Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.J Clin Oncol2013;31:2413-20

[35] Lu YC,Lu T.Treatment of patients with metastatic cancer using a major histocompatibility complex class II-restricted T-cell receptor targeting the cancer germline antigen MAGE-A3.J Clin Oncol2017;35:3322-9 PMCID:PMC5652397

[36] Vansteenkiste JF,Vanakesa T.Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol2016;17:822-35

[37] Dreno B,Smithers BM.MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.Lancet Oncol2018;19:916-29

[38] Li K,Butrin A,Linhares BM.Development of ligands and degraders targeting MAGE-A3.J Am Chem Soc2024;146:24884-91